Comparison of utility of Viladagliptin 50 mg tablet twice daily and metformin combination therapy with Vildagliptin 100 mg sustained release tablet once daily and metformin combination therapy in Indian patients with type 2 diabetes mellitus: A randomized open label phase IV clinical trial
Phase 4
Completed
- Conditions
- Health Condition 1: E119- Type 2 diabetes mellitus without complications
- Registration Number
- CTRI/2021/10/037574
- Lead Sponsor
- Dr Rudra Paul
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1 Age > 18 yrs
2 Newly Diagnosed cases with type 2 diabetes mellitus
3 HbA1C >= 6.5 & <= 8
Exclusion Criteria
ï?¶Female patients who are pregnant or lactating
1 FPG > 250mg/dl, PPPG > 350mg/dl
2 Co-morbid cardiovascular, hepatic renal and psychatric complications
3 Co-administration of drugs that are likely to interact with vildagliptin or metformin
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method